Press release
Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party
Patent EP3258951B1, Anti-PVRIG Antibodies and Methods of Use, granted by the European Patent Office covers any anti-PVRIG antibody which activates T cells
About this update from Compugen Ltd.
[{"type":"text","content":"Patent EP3258951B1, Anti-PVRIG Antibodies and Methods of Use, granted by the European Patent Office covers any anti-PVRIG antibody which activates T cells and/or NK cells for use in the treatment of cancerThe opposition division of the European Patent Office ruled to maintain the broad claims of the patent as grantedHOLON, Israel , July 17, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the broad claims of Compugen's Anti-PVRIG Antibodies for use in treating cancer patent granted by the European Patent Office, which had been under opposition, have been successfully maintained.\nOppositions were pursued by GSK and an anonymous opponent represented by a third party against EP3258951B1. In an oral proceedings hearing on July 11 2023, the opposition division of the European Patent Office ruled in favor of maintaining the broad claims in the patent as granted to Compugen. The opponents can appeal this decision.\n\"We are delighted with the decision of the opposition division of the European Patent Office ruling in favor of maintenance of the broad claims in the patent as granted, supporting our patent strategy in novel target discovery.\" said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen.\nDr. Cohen-Dayag continued, \"PVRIG is a novel immune checkpoint target, discovered by Compugen and along with TIGIT and PD-1 is part of the DNAM-1 axis. Our data suggest that in certain patients and in certain tumor types there is a need to block all three pathways in the DNAM-1 axis and we are currently leading the way in evaluating the triple blockade of PVRIG in combination with TIGIT and PD-1 in two proof of concept studies in tumors typically not responsive to immunotherapy, microsatellite stable colorectal cancer and platinum resistant ovarian cancer.\"\nCompugen was represented by Markus Rieck, LL.M., Partner, Patent Attorney, Fuchs Patentanwälte Partnerschaft mbB and Thomas Wolter, Partner, Patent Attorney, Mewburn Ellis LLP.\nAbout Compugen \nCompugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has ...